JJP 1212
Alternative Names: JJP-1212Latest Information Update: 03 Jun 2024
At a glance
- Originator JJP Biologics
- Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Fc(alpha) receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation; Linear IgA bullous dermatosis